Document Detail

Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.
MedLine Citation:
PMID:  10933364     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: This study was designed to evaluate the effects of low-dose enoximone on exercise capacity. BACKGROUND: At higher doses the phosphodiesterase inhibitor, enoximone, has been shown to increase exercise capacity and decrease symptoms in heart failure patients but also to increase mortality. The effects of lower doses of enoximone on exercise capacity and adverse events have not been evaluated. METHODS: This is a prospective, double-blind, placebo-controlled, multicenter trial (nine U.S. centers) conducted in 105 patients with New York Heart Association class II to III, ischemic or nonischemic chronic heart failure (CHF). Patients were randomized to placebo or enoximone at 25 or 50 mg orally three times a day. Treadmill maximal exercise testing was done at baseline and after 4, 8 and 12 weeks of treatment, using a modified Naughton protocol. Patients were also evaluated for changes in quality of life and for increased arrhythmias by Holter monitoring. RESULTS: By the protocol-specified method of statistical analysis (the last observation carried-forward method), enoximone at 50 mg three times a day improved exercise capacity by 117 s at 12 weeks (p = 0.003). Enoximone at 25 mg three times a day also improved exercise capacity at 12 weeks by 115 s (p = 0.013). No increases in ventricular arrhythmias were noted. There were four deaths in the placebo group and 2 and 0 deaths in the enoximone 25 mg three times a day and enoximone 50 mg three times a day groups, respectively. Effects on degree of dyspnea and patient and physician assessments of clinical status favored the enoximone groups. CONCLUSIONS: Twelve weeks of treatment with low-dose enoximone improves exercise capacity in patients with CHF, without increasing adverse events.
B D Lowes; M Higginbotham; L Petrovich; M A DeWood; M A Greenberg; P S Rahko; G W Dec; T H LeJemtel; R L Roden; M M Schleman; A D Robertson; R J Gorczynski; M R Bristow
Related Documents :
2943144 - Endocrinology of cardiac failure. pathophysiologic aspects--hemodynamics.
10197224 - Effects of severity of long-standing congestive heart failure on pulmonary function.
12015354 - Exercise training enhances baroreflex control of heart rate by a vagal mechanism in rab...
9856924 - Comparison of left ventricular function during interval versus steady-state exercise tr...
21878824 - Excess postexercise oxygen consumption is unaffected by the resistance and aerobic exer...
1678224 - Local cholinergic sweat stimulation in atopic dermatitis. an evaporimetric study.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  36     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2000 Aug 
Date Detail:
Created Date:  2000-08-17     Completed Date:  2000-08-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  501-8     Citation Subset:  AIM; IM    
Heart Failure Treatment Program, University of Colorado Health Sciences Center, Denver, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Clinical Trials, Phase II as Topic
Double-Blind Method
Electrocardiography, Ambulatory
Enoximone / administration & dosage*,  adverse effects
Exercise Test
Exercise Tolerance / drug effects*
Heart Failure / physiopathology*
Middle Aged
Phosphodiesterase Inhibitors / administration & dosage*,  adverse effects
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 77671-31-9/Enoximone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyop...
Next Document:  Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients.